Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™) (BEGIN™)

December 14, 2015 updated by: Novo Nordisk A/S

A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™: SIMPLIFY)

This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes mellitus.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

143

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Goodyear, Arizona, United States, 85395
        • Novo Nordisk Clinical Trial Call Center
      • Phoenix, Arizona, United States, 85018
        • Novo Nordisk Clinical Trial Call Center
    • California
      • Anaheim, California, United States, 92801
        • Novo Nordisk Clinical Trial Call Center
      • Chino, California, United States, 91710
        • Novo Nordisk Clinical Trial Call Center
      • Concord, California, United States, 94520
        • Novo Nordisk Clinical Trial Call Center
      • Fresno, California, United States, 93720
        • Novo Nordisk Clinical Trial Call Center
      • Greenbrae, California, United States, 94904
        • Novo Nordisk Clinical Trial Call Center
      • Palm Springs, California, United States, 92262-6972
        • Novo Nordisk Clinical Trial Call Center
    • Florida
      • Kissimmee, Florida, United States, 34741
        • Novo Nordisk Clinical Trial Call Center
    • Illinois
      • Chicago, Illinois, United States, 60616
        • Novo Nordisk Clinical Trial Call Center
    • Louisiana
      • Metairie, Louisiana, United States, 70002
        • Novo Nordisk Clinical Trial Call Center
      • Metairie, Louisiana, United States, 70006-2930
        • Novo Nordisk Clinical Trial Call Center
    • Nebraska
      • Omaha, Nebraska, United States, 68114
        • Novo Nordisk Clinical Trial Call Center
    • Nevada
      • Henderson, Nevada, United States, 89052-2649
        • Novo Nordisk Clinical Trial Call Center
    • New Hampshire
      • Dover, New Hampshire, United States, 03820
        • Novo Nordisk Clinical Trial Call Center
      • Nashua, New Hampshire, United States, 03063
        • Novo Nordisk Clinical Trial Call Center
    • New Jersey
      • Lawrenceville, New Jersey, United States, 08648
        • Novo Nordisk Clinical Trial Call Center
      • Toms River, New Jersey, United States, 08755-8050
        • Novo Nordisk Clinical Trial Call Center
    • New York
      • Albany, New York, United States, 12206
        • Novo Nordisk Clinical Trial Call Center
    • North Carolina
      • Charlotte, North Carolina, United States, 28209
        • Novo Nordisk Clinical Trial Call Center
    • Pennsylvania
      • Melrose Park, Pennsylvania, United States, 19027
        • Novo Nordisk Clinical Trial Call Center
      • Pittsburgh, Pennsylvania, United States, 15224-2215
        • Novo Nordisk Clinical Trial Call Center
    • Tennessee
      • Chattanooga, Tennessee, United States, 37411
        • Novo Nordisk Clinical Trial Call Center
      • Kingsport, Tennessee, United States, 37660
        • Novo Nordisk Clinical Trial Call Center
    • Texas
      • Austin, Texas, United States, 78731
        • Novo Nordisk Clinical Trial Call Center
      • Fort Worth, Texas, United States, 76113
        • Novo Nordisk Clinical Trial Call Center
    • Washington
      • Olympia, Washington, United States, 98502
        • Novo Nordisk Clinical Trial Call Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
  • HbA1c maximum 10 % by central laboratory analysis
  • Current treatment with basal-oral therapy (BOT) (no prandial insulin ever) consisting of: at least three months with insulin glargine once daily (average prescribed dose must have been unchanged (within plus/minus 10%) for four weeks prior to Visit 1 as confirmed by patient records or verbal confirmation by the subject) in combination with stable (unchanged doses for at least 3 months prior to Visit 1) OAD (metformin, insulin secretagogues, pioglitazone, sitagliptin or alpha-glucosidase-inhibitor) treatment in any approved (according to label) dose or combination

Exclusion Criteria:

  • Use within the last three months prior to Visit 1 of: Exenatide, Liraglutide or Thiazoledinediones (TZDs) other than Pioglitazone
  • Cardiovascular disease (CVD) defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty within the last six months prior to Visit 1
  • Recurrent severe hypoglycaemia (more than one severe hypoglycaemic episode during the last 12 months), or hypoglycaemic unawareness as judged by the Investigator, or hospitalisation for diabetic ketoacidosis during the previous six months
  • Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements
  • Previous participation in this trial. Participation is defined as started on trial medication. Rescreening of screening failures is allowed only once within the limits of the recruitment period
  • Known or suspected hypersensitivity to trial products or related products

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: IDeg 3TW
Drug: insulin degludec
Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
Experimental: IGlar/IDeg
Drug: insulin glargine
Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HbA1c (Glycosylated Haemoglobin)
Time Frame: Week 4 and Week 16
HbA1C at week 4 and 16
Week 4 and Week 16

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting Plasma Glucose (FPG)
Time Frame: Week 4 and Week 16
FPG at week 4 and 16
Week 4 and Week 16
Change in Body Weight
Time Frame: Week 0, Week 4, Week 16
Change from baseline in body weight after week 4 and after week 16
Week 0, Week 4, Week 16
Rate of Treatment Emergent Adverse Events (AEs)
Time Frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect
Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Rate of Confirmed Hypoglycaemic Episodes
Time Frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.
Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Time Frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.
Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2010

Primary Completion (Actual)

November 1, 2010

Study Completion (Actual)

November 1, 2010

Study Registration Dates

First Submitted

May 31, 2010

First Submitted That Met QC Criteria

May 31, 2010

First Posted (Estimate)

June 3, 2010

Study Record Updates

Last Update Posted (Estimate)

January 22, 2016

Last Update Submitted That Met QC Criteria

December 14, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NN1250-3839
  • U1111-1114-8802 (Other Identifier: WHO)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on insulin glargine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe